2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.67 (Poster) Evaluating Immune-Related Adverse Events in A Real-world Cohort with Lung Cancer Receiving Immunotherapy

PP01.67 (Poster) Evaluating Immune-Related Adverse Events in A Real-world Cohort with Lung Cancer Receiving Immunotherapy

Back to course

Pdf Summary

A study conducted at Tufts Medical Center aimed to evaluate the risk factors and prognosis associated with immune-related adverse events (irAEs) in lung cancer patients receiving immunotherapy. The real-world data analysis included 125 lung cancer patients who had started immunotherapy between October 2018 and September 2021. The results showed that younger age, small cell lung cancer (SCLC), and positive programmed death-ligand 1 (PDL1) expression were associated with a higher likelihood of developing irAEs. However, the occurrence of irAEs did not affect overall survival (OS) in patients with lung cancer receiving immunotherapy. The most common types of irAEs observed were endocrinopathies, pneumonitis, dermatologic and mucosal toxicity, and gastrointestinal toxicity.<br /><br />The study findings suggest that certain patient characteristics, such as age, tumor type, and PDL1 expression, may influence the development of irAEs in lung cancer patients receiving immunotherapy. However, further research is needed to confirm these findings. The results also indicate that the occurrence of irAEs does not have a negative impact on the overall survival of patients. These findings provide valuable insights into the management of irAEs and the potential benefits of immunotherapy in lung cancer treatment.<br /><br />The study has some limitations, including its retrospective design and the small sample size. Additionally, the analysis only included patients from a single medical center, which may limit the generalizability of the results. Nevertheless, the study contributes to the growing understanding of irAEs in lung cancer patients receiving immunotherapy and highlights the need for further research in this area.

Asset Subtitle

Xiao Hu

Keywords

immune-related adverse events

lung cancer

immunotherapy

risk factors

prognosis

real-world data analysis

age

tumor type

PDL1 expression

overall survival